Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.48 |
| ▸ | CASP1 | P29466 | 8/20 | 0.48 |
| ▸ | CASP7 | P55210 | 8/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526185 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2527397 | 0.98 | KDM4E (0.49) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2530279 | 0.85 | AR (0.46) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2528899 | 0.85 | AR (0.46) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2528532 | 0.85 | AR (0.46) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2163316 | 0.84 | KMT2A (0.50) | ALDH1A1KDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL2525372 | 0.83 | KDM4E (0.46) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2533216 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2529790 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4ECASP1CASP7ALOX15 | |
| SCHEMBL2529243 | 0.81 | KDM4E (0.49) | ALDH1A1KDM4EMAPTL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3873468-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-8038010-B1 | Single piece edge protector for curved objects | ILLINOIS TOOL WORKS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | ALDH1A1 2444/4885KDM4E 4191/4885CASP1 4678/4885 |
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | ALDH1A1 1424/4885KDM4E 3634/4885CASP1 1458/4885 |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | ALDH1A1 1314/4885KDM4E 4595/4885CASP1 1064/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | ALDH1A1 2444/4885KDM4E 4191/4885CASP1 4678/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | ALDH1A1 1339/4885KDM4E 4651/4885CASP1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.